Arthritis & Rheumatism · 2000 · 235 citations · 42 references
MedicineInternal MedicinePharmacotherapyClinical PharmacologyDrug RepurposingRheumatologyInflammatory ArthritisResponse AssessmentRheumatoid ArthritisArthritis EpidemiologyDisease-modifying Anti-inflammatory DrugsMortality Rate AssessmentRefractory Rheumatoid ArthritisRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis TherapyStandardized Mortality RatesStandardized Mortality Statistics
OBJECTIVE: This study investigated whether efficacious methotrexate (MTX) treatment has an impact on mortality of patients with severe rheumatoid arthritis (RA). METHODS: In this prospective, observational, one-center study, patients with severe RA refractory to other disease-modifying antirheumatic drugs started MTX treatment between 1980 and 1987. Patients were divided into 4 different groups according to their response to MTX treatment after 1 year (>50% improvement [n = 99], 20-50% improvement [n = 70], no improvement [n = 52], and discontinued treatment [n = 35]). After a followup of 7.5-15.3 years (mean 10 years), the numbers of deaths were assessed in the different groups. Standardized mortality ratios (SMR) were calculated by comparing the number of observed deaths in the study with the number of expected deaths in an age- and sex-matched sample of the general population. RESULTS: Two hundred seventy-one patients entered the study between 1980 and 1987. In 1995/1996, outcomes for 256 patients (94.5%) could be documented; 88 patients (34.4%) had died. In patients with >50% improvement after 1 year, the SMR was 1.47, while in patients with 20-50% improvement, the SMR was 1.85. In both groups combined, the SMR was 1.64 (95% confidence interval [95% CI] 1.11-2.17), compared with 4.11 (95% CI 2.56-5.66) in patients without improvement. Patients who had discontinued MTX treatment during the first year had an SMR of 5.56 (95% CI 3.29-7.83). CONCLUSION: Patients with severe RA who do not respond to MTX treatment have a poor prognosis, with >4-fold increased mortality compared with the general population, while RA patients who respond to MTX treatment have only a moderately increased mortality rate.
42
THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITIS
Otto Steinbrocker · JAMA · 1949 · 2.9K citations
revision of diagnostic criteria for rheumatoid arthritis
Marian W. Ropes, Granville A. Bennett, Steven L. Cobb et al. · 2001 · 2.2K citations
The mortality of rheumatoid arthritis
Frederick Wolfe, Donald M. Mitchell, John Sibley et al. · Arthritis & Rheumatism · 1994 · 1.3K citations
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
Michael E. Weinblatt, Jonathan S. Coblyn, David A. Fox et al. · New England Journal of Medicine · 1985 · 874 citations